Label Change will come and Afrezza will have a designation in a new category of Insulin.
ULTRA-ULTRA rapid acting insulin. Label change is in process. A true long investor knows what's ahead. Longs just have to be patience and patients will be forthcoming.
Until then we can tolerate the FUD and efforts being made to destroy Mannkind. The company is not financially as strong as an investors would like to see. So risk is there. One could lose all invested. No question about that. But the chance to win is very big too. A investor understands this but a day trader pumper does not.
The Need for Faster Insulin Problem Solved? Douglas B. Muchmore, MD First Published January 1, 2017 review-article
Article Information
Abstract Considerable progress in treatment of diabetes has been made in the nearly 100 years following the discovery of insulin, and advances in insulin therapy have improved convenience, quality of life, overall glycemic control (A1C), and risk of hypoglycemia. An unmet need remains for a mealtime insulin that can faithfully reproduce the metabolic profile that ensues following meal ingestion in healthy persons. A number of “ultra-fast” insulin programs have been initiated, and Afrezza® (insulin human; Inhalation Powder, MannKind Corporation, Danbury, CT) stands as the first such product to be approved by the US FDA. Afrezza is unique as an “ultra-ultra” fast insulin, faster than any other entrant except IV insulin. The benefits and limitations of the Afrezza profile are discussed in this analysis.
Market Data 
Markets 
AI
